LaFleur & Godfrey LLC cut its holdings in shares of Danaher Corporation (NYSE:DHR – Free Report) by 8.9% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 26,160 shares of the conglomerate’s stock after selling 2,560 shares during the period. LaFleur & Godfrey LLC’s holdings in Danaher were worth $5,168,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. MGO One Seven LLC boosted its stake in shares of Danaher by 485.7% during the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock valued at $5,145,000 after purchasing an additional 20,813 shares in the last quarter. UniSuper Management Pty Ltd boosted its stake in shares of Danaher by 1.6% during the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock valued at $34,954,000 after purchasing an additional 2,667 shares in the last quarter. Asahi Life Asset Management CO. LTD. bought a new position in shares of Danaher during the first quarter valued at approximately $539,000. Horizon Financial Services LLC boosted its stake in shares of Danaher by 20,400.0% during the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate’s stock valued at $1,681,000 after purchasing an additional 8,160 shares in the last quarter. Finally, Focus Partners Wealth boosted its stake in shares of Danaher by 10.7% during the first quarter. Focus Partners Wealth now owns 196,682 shares of the conglomerate’s stock valued at $40,328,000 after purchasing an additional 19,086 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other Danaher news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 11.10% of the company’s stock.
Danaher Trading Down 1.0%
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion during the quarter, compared to analysts’ expectations of $5.83 billion. During the same quarter in the previous year, the company earned $1.72 earnings per share. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.
Danaher Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. Danaher’s payout ratio is presently 27.23%.
Analyst Ratings Changes
DHR has been the topic of several analyst reports. Scotiabank raised shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price target on the stock in a report on Friday, July 11th. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a report on Tuesday, September 2nd. Deutsche Bank Aktiengesellschaft cut their price target on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. UBS Group cut their price target on shares of Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, July 23rd. Finally, Barclays reaffirmed an “overweight” rating and issued a $225.00 price target (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Seventeen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus target price of $246.35.
Get Our Latest Report on Danaher
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
- Five stocks we like better than Danaher
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3 Overlooked Value Stocks Set to Surge as Rates Drop
- The 3 Best Fintech Stocks to Buy Now
- Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
- Conference Calls and Individual Investors
- After the Fed’s Rate Cut, PNC Could See a Mortgage Refinance Boom
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.